BEYZA ŞİRİN ÖZDEMİR, GAMZE MELEK AKSU, AYLİN FİDAN KORCUM, TAYLAN BÜKÜLMEZ, MİNE GENÇ, MELEK NUR YAVUZ
Turkish Journal of Oncology - 2018;33(1):1-6
OBJECTIVE Concurrent chemoradiotherapy is the primary treatment for patients with locally advanced cervical cancer. We evaluated the treatment results and prognostic factors in patients treated with chemoradiation. METHODS We retrospectively reviewed the records of 150 patients with locally advanced cervical cancer treated with curative chemoradiotherapy between 1999 and 2014 at our hospital. RESULTS The median follow-up period was 37.5 months (range: 5.6-186 months). All patients received both external beam radiation therapy (EBRT) and intracavitary brachytherapy. EBRT was delivered with conventional 2-dimensional radiotherapy or 3-dimensional conformal radiotherapy (3DCRT). Eighty-seven percent of patients received cisplatinum-based chemotherapy during EBRT. Total or nearly total remission was achieved in 72% of patients. With a median follow-up duration of 37.5 months, 29% of patients died, 13% of patients had local-regional recurrence, and 25% of patients had distant metastasis. The 2-, 5-, and 10-year overall survival rates were 76%, 62%, and 47%, respectively, and the progression-free survival rates were 68%, 62%, and 58%, respectively. We evaluated prognostic factors for overall survival and progression-free survival. The most important prognostic factor was the radiotherapy technique. The survival curves were estimated by the Kaplan-Meier method, and differences were assessed using the log-rank test; a p-value<0.05 was considered significant. CONCLUSION Chemoradiotherapy is an effective and tolerable treatment method for patients with cervical cancer. These patients treated with 3DCRT have a better overall survival.
